Abzu announces Victor Galindo as new CEO.

Former CTO Victor Galindo steps up as CEO to propel Abzu’s vision of explainable AI.

Victor Galindo, CEO of Abzu

Victor Galindo, CEO of Abzu.

Abzu, the best-in-class in silico disease understanding and drug design company, today announced the appointment of Victor Galindo as its new Chief Executive Officer. Victor, a co-founder of Abzu and previously Abzu’s Chief Technology Officer, succeeds Casper Wilstrup, who has been steering the company since 2018.

Over the past 6.5 years at Abzu, Victor has been a key architect and engineer in developing Abzu’s proprietary, explainable AI, the QLattice®, and Abzu’s offerings in the design and delivery of RNA therapeutics. Victor has also been essential in applying the QLattice in disease understanding and drug design in new therapeutic modalities.

“I am honored to lead Abzu and build on the strong foundation laid down by Casper,” says Victor Galindo, “with an excellent track record in scientific citations and the achievements of our proprietary, explainable AI, I see a promising future for Abzu in all of life science. The QLattice is, at its core, an AI fit for science. And I look forward to bringing it to more scientists.”

Victor is an Industrial Engineer by education, with a history in chemical and materials research, and has over 12 years’ experience in engineering and software development. “Victor is a natural choice to become Abzu’s CEO,” says Casper Wilstrup, former CEO of Abzu. “Transparency and trust have always been central to who we are and our technology, and he will keep our proprietary, explainable AI as the cornerstone of Abzu’s approach.”

“After over six incredible years filled with amazing highs and a few tough lows, I’m ready for a break. I’m proud to announce that my co-founder and CTO, Victor Galindo, will be stepping into the CEO role. I have complete confidence in his leadership and ability to take Abzu to the next level,” says Casper. Casper will continue to be a part of Abzu as a member of Abzu’s advisory board.

About Abzu.

Abzu is the best in class in silico disease understanding and drug design company. Since its founding in 2018, Abzu’s proprietary explainable AI, the QLattice®, has been the cornerstone to their cutting-edge approach. Abzu is a preferred partner for pharma, biotech, and research institutions, transforming data into insights and accelerating R&D.

Abzu has offices in Copenhagen and Barcelona, and has received €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool Vendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards. For more information, visit www.abzu.ai.

Share this press release.

The latest press releases from Abzu.

Abzu leads the way in disease understanding and drug design.

Christian Lund joins Abzu’s board of directors.

October 10, 2023
Christian Lund, co-founder of Templafy, joins the board of directors at Abzu, the Danish-Spanish startup that builds and applies trustworthy AI to tackle complex challenges for the world’s leading companies.

Abzu welcomes Kasper Sommer as its new CFO.

October 4, 2023
Abzu, the Danish/Spanish startup that builds trustworthy AI to tackle complex challenges for the world's leading companies., welcomes Kasper Sommer as its new Chief Financial Officer.

Abzu earns ISO 27001:2022 certification: Elevating trust with ISO-certified AI.

October 3, 2023
Abzu, the Danish-Spanish startup that builds and applies trustworthy AI to tackle complex challenges for the world’s leading companies, secures ISO 27001:2022 certification, reinforcing its value proposition for explainable, resilient, and safe AI solutions.

Subscribe for
notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.